Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. PANW
3. CL
4. SNDK
5. TAP
6. DELL
7. ROIV
8. ANET
9. NKE
10. BE

Go back to Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder
(NYSE: ANRO) Delayed: 35.55 -0.85 (2.34%)
Previous Close $36.40    52 Week High $ 
Open $36.17    52 Week Low $ 
Day High $36.98    P/E N/A 
Day Low $35.45    EPS $ 
Volume 269,947